Elafibranor
| CAS No. | 824932-88-9 | Cat. No. | BCP31152 |
| Name | Elafibranor | ||
| Synonyms | GFT505;GFT 505;GFT-505; | ||
| Formula | C22H24O4S | M. Wt | 384.49 |
| Description | Elafibranor is a multimodal and pluripotent medication for treatment of atherogenic dyslipidemia for an overweight patient with or without diabetes. It is an oral treatment that acts on the 3 sub-types of PPAR (PPARa, PPARg, PPARd) with a preferential action on PPARa. As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress. | ||
| Pathways | Cell Cycle/DNA Damage | ||
| Targets | PPAR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.